Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters









Database
Language
Publication year range
1.
Comment on "ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models".
Tesseur, Ina; Lo, Adrian C; Roberfroid, Anouk; Dietvorst, Sofie; Van Broeck, Bianca; Borgers, Marianne; Gijsen, Harrie; Moechars, Diederik; Mercken, Marc; Kemp, John; D'Hooge, Rudi; De Strooper, Bart.
Science ; 340(6135): 924-e, 2013 May 24.
Article in English | MEDLINE | ID: mdl-23704554

ABSTRACT

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential ß-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.


Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Apolipoproteins E/metabolism , Brain/metabolism , Tetrahydronaphthalenes/pharmacology , Tetrahydronaphthalenes/therapeutic use , Animals , Male
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL